
A Phase I clinical trial was performed on patients with solid tumors zzso to conventional zzso zzso was administered zzso for 30 consecutive days at doses ranging from zzso to zzso zzso Patients entered the study after providing a written informed zzso Although 26 patients were entered only 23 were zzso zzso zzso zzso toxicity evidenced as zzso because of zzso of the external zzso muscles was present in 13 zzso It started at doses of zzso zzso and lasted from 2 to 6 zzso These episodes did not require dose adjustment and disappeared in 1-3 weeks of zzso Three patients experienced zzso zzso zzso zzso zzso and anxiety zzso zzso at the zzso toxicity of zzso zzso Also at zzso zzso 1 patient showed zzso zzso 2) and anxiety zzso 3) without evidence of zzso zzso zzso increases zzso zzso in the levels of zzso zzso zzso zzso and zzso zzso attributed to zzso zzso were observed but returned to normal by the last week of zzso At zzso zzso there was a case of zzso zzso reaction on day 31, which required zzso zzso was regarded as an adverse drug-related reaction, and the patient was removed from the zzso Two patients at different doses zzso zzso and zzso zzso had zzso Four patients had zzso transient increase in blood pressure (up to 20 zzso zzso 12 h after the first injection, which lasted 24 zzso No treatment was required and toxicity did not zzso Six patients experienced slight zzso during the first 2 zzso The maximum tolerated dose was set at zzso zzso zzso measurable partial responses zzso reduction of tumor zzso were noted in 2 patients treated at zzso zzso and 1 at zzso zzso One patient (at zzso zzso presented a complete response on day zzso zzso zzso showed rapid zzso from the injection site to blood zzso zzso zzso zzso zzso zzso zzso Plasma concentration reached a peak zzso zzso zzso zzso zzso zzso at zzso zzso 19 zzso 3 zzso The zzso of the distribution zzso phase is 22 zzso 2 zzso Starting at zzso h after injection, the decrease in plasma concentration becomes zzso reaching 14 zzso 3 zzso 24 h after zzso The profile is dominated by the elimination zzso phase with a zzso of zzso zzso zzso zzso zzso 24 h after the injection ( approximately 5 zzso zzso of the product was zzso The area under plasma concentration versus time curve was zzso zzso zzso zzso Assuming availability zzso approximately 1, the clearance is zzso zzso zzso zzso 7 zzso and the apparent volume of distribution is zzso zzso 12 zzso 3 zzso The recommended dose for a Phase II study is zzso zzso 

